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Abstract
Introduction Preterm birth (PTB) is defined as birth occurring before 37 weeks’ gestation, affects 5–9% of all pregnancies in 
developed countries, and is the leading cause of perinatal mortality. Spontaneous preterm birth (sPTB) accounts for 31–50% 
of all PTB, but the underlying pathophysiology is poorly understood.
Objective This study aimed to decipher the lipidomics pathways involved in pathophysiology of sPTB.
Methods Blood samples were taken from SCreening fOr Pregnancy Endpoints (SCOPE), an international study that recruited 
5628 nulliparous women, with a singleton low-risk pregnancy. Our analysis focused on plasma from SCOPE in Cork. Dis-
covery profiling of the samples was undertaken using liquid chromatography-mass spectrometry Lipidomics, and features 
significantly altered between sPTB (n = 16) and Control (n = 32) groups were identified using empirical Bayes testing, 
adjusting for multiple comparisons.
Results Twenty-six lipids showed lower levels in plasma of sPTB compared to controls (adjusted p < 0.05), including 20 
glycerophospholipids (12 phosphatidylcholines, 7 phosphatidylethanolamines, 1 phosphatidylinositol) and 6 sphingolipids (2 
ceramides and 4 sphingomyelines). In addition, a diaglyceride, DG (34:4), was detected in higher levels in sPTB compared 
to controls.
Conclusions We report reduced levels of plasma phospholipids in sPTB. Phospholipid integrity is linked to biological 
membrane stability and inflammation, while storage and breakdown of lipids have previously been implicated in pregnancy 
complications. The contribution of phospholipids to sPTB as a cause or effect is still unclear; however, our results of dif-
ferential plasma phospholipid expression represent another step in advancing our understanding of the aetiology of sPTB. 
Further work is needed to validate these findings in independent pregnancy cohorts.
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1 Introduction
Preterm birth (PTB) is defined as birth occurring before 
37 weeks of gestation and can be spontaneous or iatrogenic. 
Preterm delivery rates vary between countries, but are esti-
mated to be 5–9% of pregnancies in Europe and other devel-
oped countries, with rates still rising in most industrialised 
countries (Goldenberg et al. 2008; Slattery and Morrison 
2002). PTB accounts for 75% of perinatal deaths, with two-
thirds of these deaths occurring in preterm infants delivered 
before 32 weeks of gestation (Slattery and Morrison 2002). 
Spontaneous preterm birth (sPTB) is estimated to occur in 
31–50% of all PTB (Slattery and Morrison 2002) and the 
pathways involved are not yet fully understood. A previous 
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study of low-risk nulliparous pregnant women in an interna-
tional cohort, SCreening fOr Pregnancy Endpoints (SCOPE) 
study (www.scope study .net), used clinical data to determine 
risk factors linked to two sub-phenotypes of sPTB, sPTB 
with intact membranes (sPTB-IM) and sPTB occurring after 
prelabour rupture of membranes (sPTB-PPROM). Charac-
teristics such as marijuana use before conception, shorter 
cervical length, or strong family history of low birth weight, 
were linked to higher risks of sPTB. However, the models 
built using the reported risk factors were not robust enough 
to predict sPTB (Dekker et al. 2012). Indeed, the area under 
the curve (AUC) of the model for sPTB-IM was 0.69, with 
a 0.39 sensitivity based on 90% specificity; the model for 
sPTB-PPROM showed an AUC of 0.79, with 0.49 sensitiv-
ity based on 90% specificity. As a result, research efforts 
have focused on finding blood based biomarkers for early 
diagnosis and intervention.
Metabolites are intermediate compounds involved in bio-
chemical processes and are a reflection of cellular metabolic 
pathways of the organism. Similarly, lipids are a subset of 
metabolites which form the matrix of our cell membranes 
and support a variety of biological functions such as energy 
storage, cell metabolism, and cell signalling. Together, 
metabolites and lipids levels are regulated in response to 
environmental modifications (Goodacre et al. 2004), and as 
such, are a direct reflection of the phenotype (Patti et al. 
2012); this makes them ideal candidates for biomarkers and 
therapeutic targets. Several recent studies have used metabo-
lomics methods for biomarker discovery of PTB in plasma 
(Lizewska et al. 2018), in amniotic fluid samples (Menon 
et al. 2014; Romero et al. 2010), and in cervicovaginal 
secretions (Auray-Blais et al. 2011). A systematic review 
performed on the literature between 1965 and 2008 showed 
that various sample types have been used for the study of 
biomarkers of spontaneous preterm birth (Menon et  al. 
2011), and 46.2% of included studies used maternal blood 
samples, 31.0% used amniotic fluid samples, and 1.2% used 
urine samples. In addition, the collection of blood sample is 
minimally invasive compared to the collection of amniotic 
fluid for example, which can present risks for the fetus (Beta 
et al. 2018).
In recent years, several studies have linked altered levels 
of lipids and higher risk of adverse pregnancy outcomes 
(Baig et al. 2013; Jiang et al. 2017; Reece et al. 1997). 
Baig et al. have demonstrated that altered levels of glyc-
erophospholipids and sphingolipids in syncytiotrophoblast 
microvesicles shed from the placenta, are associated with 
increased risk of preeclampsia or recurrent miscarriages 
(Baig et al. 2013). Reece et al. have shown an association 
between preterm birth (< 37 weeks of gestation) and higher 
levels of arachidonic acid and docosapentaneoic acid lev-
els in maternal blood samples taken at the time of deliv-
ery (Reece et al. 1997). Jiang et al. preformed a systematic 
review aiming to analyse the associations between altered 
maternal lipids levels (cholesterol, triglycerides, high and 
low lipoprotein-cholesterol), and the risk of preterm birth 
(Jiang et al. 2017). Their meta-analysis showed that altered 
maternal levels of lipids are associated with a higher risk 
of preterm birth, for either higher levels [pooled OR for 
elevated levels 1.68 (95% CI 1.24–2.26)], or lower levels 
[pooled OR 1.52 (95% CI 1.13–3.82)].
To date, no study has identified metabolites or lipids 
robust enough to be used as biomarkers of PTB, as they 
need to be validated in different populations, using larger 
sample sizes. Here we describe the first discovery lipidomics 
study to be undertaken in sPTB. The aim of this discovery 
profiling study was to help determine the clinically relevant 
lipidomic pathways involved in the aetiology of sPTB. 
For this purpose, lipidomics profiles were obtained from 
plasma samples taken at 20 weeks of gestation from women 
recruited to the SCOPE study in Cork, Ireland (Kenny et al. 
2014).
2  Materials and methods
2.1  Study participants
Flow chart of participant selection and samples preparation 
are presented in Fig. 1. Selected participants were women 
recruited through the SCOPE study (www.scope study .net), 
in Cork, Ireland. SCOPE is an international longitudi-
nal birth cohort that recruited over 5000 healthy nullipa-
rous women with singleton pregnancies in Australia, New 
Zealand, the United Kingdom and Ireland (Kenny et al. 
2014). Written informed consent and ethical approval were 
obtained prior to sample collection [ECM5 (10) 05/02/08]. 
In Cork SCOPE sub-cohort, 1773 women were recruited, 
including 56 women with spontaneous preterm birth before 
37 weeks of gestation, which represents approximately 3% 
of this population. In the present cross-sectional study from 
a prospectively collected birth cohort, we chose to focus 
on women who had an “early” spontaneous preterm birth, 
defined as spontaneous preterm birth < 34 weeks of gestation 
(n = 16, 0.9% of Cork SCOPE population). Plasma samples 
were collected at 20 weeks of gestation, and women who 
later delivered prematurely before 34 weeks of gestation 
(cases) were matched to women who had an uncomplicated 
pregnancy (controls). Controls (n = 32) were matched to 
cases (n = 16) according to age (± 5 years), and body mass 
index (BMI, ± 3.0 kg/m2). Detailed clinical and demographic 
data is presented in Table 1.
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2.2  Reagents and materials
Liquid chromatography grade iso-propanol (IPA), acetoni-
trile (ACN) and ammonium formate were purchased from 
Fisher Scientific (Loughborough, UK). LC–MS glass vials 
and ultra-performance liquid chromatography (UPLC) 
columns were purchased from Waters (Waters, Wexford, 
Ireland).
2.3  Sample preparation
Heparinised plasma samples taken from participants at 
20 weeks’ gestation were randomised before extraction. 
Samples were taken out of – 80 °C storage and allowed to 
thaw on ice, before being transferred to labelled Eppendorf 
tubes (200 µl). Lipids were extracted as previously described 
(Sarafian et al. 2014), iso-propanol (IPA) chilled at – 20 °C 
was added (600 µl) to the plasma. Samples were then vortex 
mixed for 1 min and incubated for 10 min at room tempera-
ture, then stored at – 20 °C overnight to improve protein 
precipitation. The following day, samples were centrifuged 
at 14,000×g for 20 min at room temperature. For each sam-
ple, the supernatant was transferred in correctly labelled LC 
vials. For quality control, a volume of 30 µl was taken from 
each sample, pooled in a tube and vortexed to create pooled 
quality control samples (QC). A volume of 100 µl of pooled 
samples were aliquoted in different QC vials.
2.4  Global lipidomics profiling analysis
Samples were analysed using an ultra-high performance 
liquid chromatography quadrupole time-of-flight (UPLC-Q-
TOF) mass spectrometry. The UPLC system was a Waters 
ACQUITY system (Waters Corp, Wilmslow, UK), coupled 
with a BEH C18, 1.7 µm, 2.1 × 100 mm analytical column 
(Waters Corp, Wexford, Ireland). The samples were analysed 
in a randomised order, and as technical triplicates, with an 
injection volume of 4 µl (ESI+ ) and 7 µl (ESI−). Pooled 
quality control samples (QC) were injected to condition 
the column (n = 8 injections) prior to the start of the analy-
sis, and thereafter every tenth injection. A 23 min gradient 
elution was applied at a flow rate of 0.4 ml/min using two 
Fig. 1  Flow chart of participant 
selection, samples preparation 
and analysis
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mobile phases, a mix of ACN and water (60:40, v:v) with 
10 mM of ammonium formate (A), and a mix of IPA and 
ACN (90:10, v:v) with 10 mM of ammonium formate (B). 
The elution gradient was as follows: initial conditions at 
30% B; from 1 to 15 min increased up to 99% B; from 15 to 
20 min, maintained at 99% B; from 20 to 22 min decreased 
Table 1  Demographic and clinical data of the study population
Values are shown as mean (SD), median (interquartile range) or n (%)
BMI body mass index, SGA small for gestational age, NA not applicable; all mothers were nulliparous
a Customised birthweight centile: adjusted for mother’s height, weight at 15 weeks visit, ethnicity, sex and weight of baby and gestation at deliv-
ery of baby
Control (n = 32) Case (n = 16) p value
Age (years) 29.69 (5.03) 30.31 (6.93) 0.723
BMI, grouped according to World Health Organisation
 0– < 18.5, underweight 0 1 (6.2) 0.555
 ≥ 18.5 and < 25, normal weight 16 (50.0) 7 (43.8)
 ≥ 25 and < 30, overweight 8 (25.0) 4 (25.0)
 ≥ 30, obese 8 (25.0) 4 (25.0)
Ethnicity
 Caucasian 32 (100) 16 (100) NA
 Asian 0 0
 Pacific Islander 0 0
 Maori 0 0
Marital status
 Single 1 (3.1) 6 (37.5) 0.006
 Married 21 (65.6) 7 (43.8)
 Stable relationship 10 (31.3) 3 (18.8)
Years of schooling 14 (13–14) 13.5 (13–14) 0.801
Years of schooling, in groups
 < 12 years 0 2 (12.5) 0.120
 12 or 13 years 15 (46.9) 6 (37.5)
 > 13 years 17 (53.1) 8 (50.0)
Job situation
 Full time work 25 (78.1) 12 (75.0) 0.130
 Part time work 4 (12.5) 0
 Homemaker 2 (6.3) 0
 Unemployed 1 (3.1) 2 (12.5)
 Student 0 1 (6.3)
 Sickness beneficiary 0 1 (6.3)
Socioeconomic index 45.66 (19.02) 35.81 (13.31) 0.044
Smoking status at first visit (15 weeks)
 Never smoked 23 (71.9) 10 (62.5) 0.642
 Smoked pre-pregnancy, but quit smoking before pregnant 0 0
 Smoked in pregnancy, but quit before first visit 6 (18.8) 3 (18.8)
 Smoking at first visit (15 weeks) 3 (9.4) 3 (18.8)
Alcohol status at first visit (15 weeks)
 Never consumed alcohol 3 (9.4) 3 (18.8) 0.734
 Consumed alcohol pre-pregnancy, but quit before conception 4 (12.5) 1 (6.3)
 Consumed alcohol in pregnancy, but quit before first visit 20 (62.5) 9 (56.3)
 Continuing to drink at first visit 5 (15.6) 3 (18.8)
Birthweight (g) 3560 (3385–3775) 1665 (1102.5–2070) < 0.001
Customised birthweight  centilea 47.6 (34.18–81.1) 15.1 (9.03–73.85) 0.076
Gestational age at delivery (weeks) 40.50 (39.79–41.40) 32.29 (28.75–33.36) < 0.001
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to 30% B; from 22 to 23 min, returned to initial conditions 
of 30% B. During the analysis, samples were maintained at 
4 °C and the column at 65 °C Mass spectrometry analysis 
was performed using a Synapt G2-S Q-ToF (Waters Corp, 
Wilmslow, UK) with data collected in continuum format 
using positive and negative electrospray ionisation (ESI±). 
The data independent acquisition (DIA) mode,  MSe (Bate-
man et al. 2002; Silva et al. 2005) was used for data acqui-
sition. Data were acquired from 50 to 1500 m/z range, in 
resolution mode. Precursor (low energy) and fragment (high 
energy) ion data were collected within the same acquisition 
with a scan time of 0.1 s for each, providing a total cycle 
time of 0.2 s. In the case of high energy, a linear collision 
energy ramp (20–40 eV) was applied over the 0.1 s scan. 
Capillary voltage was set to 1.5 kV, sampling cone to 30 V 
and extraction cone to 5 V. The source was set at 120 °C, 
and desolvation temperature at 650 °C. Desolvation gas 
flow rate was set at 800 l/h and cone gas at 50 l/h. Detector 
set up was performed using leucine enkephalin (LeuEnk) 
(Waters, Wexford, Ireland) and SYNAPT was calibrated 
using sodium formate (Waters, Wexford, Ireland), according 
to manufacturer’s instructions. Real time lock-mass correc-
tion was achieved by infusing LeuEnk at 10 μl/min through 
a lock-spray probe and acquired every 30 s.
2.5  Data pre‑processing
MSe data were processed using Progenesis QI version 2.4 
(Nonlinear dynamics, Newcastle, UK). Progenesis QI is a 
data analysis software package that accurately processes 
LC–MS data, based on accurate mass measurements, 
isotopic fit and fragmentation data. Data were chromato-
graphically aligned using an appropriate pooled QC as the 
alignment reference. Data were peak picked and normal-
ised to all compounds. Adducts corresponding with M + H, 
M + H-H2O, M + H − 2H2O, M + NH4, M + Na, M + K, 
M + 2H, M + 2Na were considered during peak picking. 
Compound measurements (raw and normalised compound 
abundances) were exported from Progenesis QI for down-
stream statistical analysis.
2.6  Statistical analysis
For statistical analysis of the demographic and clinical 
data we applied the Student T test, Mann–Whitney U test, 
or Pearson χ2 test, and multiple comparisons corrections 
as appropriate (IBM SPSS Statistics 24). Results were 
considered statistically significant if the p value was less 
than 0.05 (Table 1). Randomisation of samples before 
preparation was performed using block randomisation 
based on the patients’ BMI and the outcome. No signifi-
cant dependency between measurement order, the outcome 
and biometric and clinical information about patients was 
observed (p < 0.05; Mann–Whitney U test, Spearman cor-
relation, Chi square test and Kruskal–Wallis test as appli-
cable; Benjamini and Hochberg step-up FDR-controlling 
procedure) (Benjamini and Hochberg 1995).
Statistical analyses of UPLC-MS data were performed 
using the R statistical software (R Core Team 2013) and 
the Bioconductor package limma (Ritchie et al. 2015). 
UPLC-MS analyses were performed with two electro-
spray ionisation (ESI) modes (ESI+  and ESI−), which 
differ significantly in their analytical sensitivity and tech-
nical variability and therefore analysed independently. 
Briefly, median normalisation was performed on the raw 
UPLC-MS data to correct for the systematic measure-
ment biases known to be associated with the UPLC-MS 
platform used. Quality control procedures were applied 
to check for systematic measurement biases (Broadhurst 
et al. 2018). Measurement precision was checked for each 
feature by computing the missing rate and coefficient of 
variation (CV) over the replicate measurements. Features 
with a missing rate greater or equal to 20% and features 
with a CV greater or equal to 30% were not considered in 
subsequent analyses. Features predictive for the outcome 
were selected using the empirical Bayes method, adjusting 
the design for replicate measures (Smyth 2004). Empirical 
Bayes methods have been successfully applied on LC–MS 
data (Kammers et al. 2015; Margolin et al. 2009), and 
offer the advantage of correcting for false discovery rate 
while identifying differential features. This approach was 
verified by comparing them to feature selection made 
using Mann–Whitney U test, on the average measurement 
per patient with multiple testing correction. Agreement 
between the two methods was demonstrated (Data not 
shown).
2.7  Putative annotation of lipids
The exact mass of features with a significant adjusted 
value (p < 0.05) were searched against the Human Metab-
olome Database version 4.0 (Wishart et al. 2018), Lipid 
Maps version of January 2019 (Cotter et al. 2007) and 
Chemspider (searching the databases ChEBI version of 
February 2018, and KEGG version of April 2014; https ://
www.chems pider .com), using the Progenesis QI identifi-
cation tool. Search parameters were set for an exact mass 
tolerance of 5 and 10 ppm, for precursor and fragment 
ions respectively. Putative annotations were then manu-
ally verified when fragmentation data was available, as 
shown in Supplementary Material 1. In accordance with 
the MSI reporting standards, we have achieved metabolite 
identification level 2, or putatively annotated compounds 
(Salek et al. 2013).
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3  Results
We undertook lipidomics analysis of plasma samples from 
women participating in the SCOPE pregnancy cohort in 
Cork, Ireland. Samples were collected at 20 weeks’ gesta-
tion, and selected cases (delivery before 34 weeks’ gesta-
tion) were matched to controls according to age, BMI and 
ethnicity (Table 1). The clinical data analysis showed that 
women who had a spontaneous preterm birth were more 
likely to be married (43.5%), or single (37.5%), while only 
18.8% were in a stable relationship. The ESI+  data set 
generated for analysis included 5878 features, and prin-
cipal component analysis (PCA) and volcano plots are 
shown in Fig. 2a and c. After data pre-processing, data 
filtration (as described above), statistical analysis was 
performed using empirical Bayes methods on 4845 fea-
tures. We putatively annotated 45 features as significantly 
differentially expressed between cases and controls, of 
which 27 remained significant following correction for 
multiple testing (Table 2). Of these 27 annotated lipids, 
26 are phospholipids: 20 glycerophospholipids (12 phos-
phatidylcholines (PC), 7 phosphatidylethanolamines (PE), 
and 1 phosphatidylinositol (PI)), and 6 sphingolipids (2 
Fig. 2  PCA score plot of all samples in ESI+  (a) and in ESI− (b) 
and respective volcano plots (c and d). In PCA plots, blue dots rep-
resent sPTB case samples, yellow triangles represent control samples, 
and grey squares represent QC samples. Volcano plots show  log2 
fold change plotted against –log10 of adjusted p values in ESI+  (c) 
and ESI − (d), plotted in blue are the variables with an adjusted p 
value < 0.05
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ceramides and 4 sphingomyelins (SM)). Notably, all phos-
pholipids were significantly lower in cases compared to 
controls. The last metabolite identified was a diglyceride, 
(DG (34:4)), detected at higher levels in sPTB compared to 
controls. Box plots of significant metabolites annotated in 
the Cork cohort are represented in Supplementary Material 
2. The ESI-data set generated a total of 769 features, PCA 
and volcano plots are shown in Fig. 2b and d, and after 
data pre-processing, data filtration, and statistical analysis, 
no features were found to be significantly altered in sPTB 
group compared to control group. 
4  Discussion and conclusions
Our study provides the first evidence that altered plasma 
phospholipids expression at 20 weeks’ gestation is asso-
ciated with the onset of sPTB, and our findings are of 
broad relevance to “at risk” pregnancy states. Sphingolipid 
metabolism and glycerophospholipid metabolism are 
involved in pertinent molecular processes such as storage 
and breakdown of lipid molecules for energy, apoptosis, 
inflammation, and cell-membrane stabilisation (Baig et al. 
2013). The sphingolipid and glycerophospholipid path-
ways are also interconnected and of mutual dependence, 
therefore it is plausible that an overall reduction in phos-
pholipids are implicated in the pathophysiology of sPTB 
(Fig. 3). Alterations in phospholipid metabolism have 
previously been associated with pregnancy complications 
(Baig et al. 2013; Horgan et al. 2011) and animal models 
of pregnancy loss (Mizugishi et al. 2007), and our study 
represents a further step in understanding the involvement 
of phospholipid metabolism in sPTB. Future measures of 
altered phospholipid metabolism such as ELISA based 
technology, and integrated multi-omics techniques should 
Table 2  Putatively annotated lipids that were significantly (p < 0.05) altered in spontaneous preterm (sPTB) group compared to control
Bold: adjusted p value < 0.05. Fold change reported with 95% confidence interval
Cer ceramide, CerP ceramide-1-phosphate, DG diglyceride, PC phosphatidylcholine, PE phosphatidylethanolamine, PE-Cer ceramide phos-
phoethanolamine, PI phosphatidylinositol, SM sphingomyeline
Identification Chemical class p value Adjusted p value Direction Fold change (95% CI)
PC(35:1) Glycerophospholipid 2.06E−05 1.46E−02 Down 1.23 (1.11–1.39)
PC(40:5) Glycerophospholipid 1.30E−04 2.43E−02 Down 1.26 (1.10–1.45)
PC(42:4) Glycerophospholipid 5.53E−08 7.11E−04 Down 1.19 (1.12–1.26)
PC(42:5) Glycerophospholipid 2.75E−05 1.21E−02 DOWN 1.15 (1.07–1.27)
PC(O-38:4) Glycerophospholipid 5.40E−06 1.22E−02 Down 1.16 (1.07–1.26)
PC(O-42:4) Glycerophospholipid 7.51E−06 7.51E−03 Down 1.20 (1.09–1.26)
PC(O-44:6) Glycerophospholipid 4.68E−05 2.14E−02 Down 1.13 (1.06–1.19)
PC(P-36:1) Glycerophospholipid 8.61E−05 2.73E−02 Down 1.17 (1.07–1.26)
PC(P-38:3) Glycerophospholipid 6.33E−05 2.14E−02 Down 1.13 (1.07–1.20)
PC(P-40:3) Glycerophospholipid 8.19E−05 2.14E−02 Down 1.23 (1.14–1.36)
PC(P-40:4) Glycerophospholipid 2.75E−05 2.11E−02 Down 1.12 (1.06–1.18)
PC(P-40:5) Glycerophospholipid 2.79E−08 6.57E−04 Down 1.20 (1.12–1.29)
PE(38:0) Glycerophospholipid 9.60E−06 9.12E−03 Down 1.21 (1.11–1.29)
PE(38:1) Glycerophospholipid 3.26E−05 3.69E−02 Down 1.13 (1.06–1.21)
PE(38:2) Glycerophospholipid 7.61E−05 2.14E−02 Down 1.21 (1.09–1.34)
PE(40:3) Glycerophospholipid 1.31E−05 9.56E−03 Down 1.23 (1.12–1.35)
PE(40:4) Glycerophospholipid 1.70E−05 9.68E−03 Down 1.16 (1.09–1.26)
PE(42:6) Glycerophospholipid 9.97E−06 7.12E−03 Down 1.51 (1.27–1.78)
PE-Cer(38:3) Glycerophospholipid 3.34E−06 2.71E−02 Down 1.17 (1.11–1.22)
PI(35:0) Glycerophospholipid 4.83E−05 2.99E−02 Down 2.19 (1.53–3.17)
CerP(44:1) Sphingolipid 7.17E−05 2.14E−02 Down 1.21 (1.10–1.30)
GalactosylCer(42:2) Sphingolipid 2.48E−07 1.07E−03 Down 1.19 (1.12–1.27)
SM(32:2) Sphingolipid 7.37E−05 2.58E−02 Down 1.16 (1.08–1.26)
SM(34:1) Sphingolipid 1.25E−04 4.63E−02 Down 1.17 (1.09–1.25)
SM(35:1) Sphingolipid 9.00E−07 7.68E−03 Down 1.28 (1.17–1.40)
SM(38:2) Sphingolipid 9.68E−06 1.21E−02 Down 1.14 (1.08–1.20)
DG(34:4) Fatty acyl 1.29E−04 2.99E−02 Up 1.20 (1.08–1.33)
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be investigated—all of which hold promise for developing 
prognostic biomarkers for at risk pregnancy states.
Using a unique prospective cohort, we investigated 
blood plasma samples at 20 weeks’ gestation, from women 
whose pregnancies ended in sPTB (< 34 weeks of gesta-
tion) in comparison to matched controls, i.e. women who 
had uncomplicated pregnancies. We specifically putatively 
annotated 20 glycerophospholipids and 6 sphingolipids as 
differentially expressed following correction for multiple 
testing, and the uniform decreased expression of these two 
phospholipid groups was particularly striking in the sPTB 
group (see Fig. 2). In support of our observations in sPTB 
in SCOPE Cork, a recent metabolomic profiling study in the 
same cohort of women implicated bile acids, prostaglan-
dins and Vitamin D as differentially expressed at 15 and 
20 weeks’ gestation (Considine et al. 2019). This independ-
ent study which was performed at the University of Man-
chester, profiled metabolites using alternative extraction pro-
tocols (Dunn et al. 2011) and LC–MS/MS analyses. Despite 
different preparation methods and analytical analyses, both 
studies report increased fatty acids levels and reduced dia-
cylglycerophosphoinositol in sPTB. Together, these stud-
ies provide complementary evidence for the implication of 
metabolomic and lipidomic pathways in the pathophysiology 
of sPTB and suggest dysregulation on a systems level.
In further support of altered lipid profiles in adverse 
pregnancy outcomes, Baig et al. (2013) reported altered 
glycerophospholipids and sphingolipids in placental syn-
cytiotrophoblast microvesicles, in preeclampsia, which are 
shed from the placenta into maternal circulation (Baig et al. 
2013). Evidence from animal models of at risk pregnancy 
also implicate altered lipid metabolism, whereby Mizugishi 
et al. (2007) reported that a critical enzyme of sphingolipid 
metabolism (sphingosine kinase, Sphk) was knocked out, 
resulting in early pregnancy loss in mice (Mizugishi et al. 
2007). Finally, our findings of altered phospholipids in sPTB 
may be broadly related to the pathophysiology of obstetric 
antiphospholipid syndrome (OAPS), an auto-immune dis-
ease consistently associated with pregnancy complications. 
OAPS is characterised by presence of circulating antiphos-
pholipid antibodies (aPL) (Antovic et  al. 2018). These 
aPLs target a circulating blood protein, β2-glycoprotein I 
(β2-GPI), that has high affinity and binds to phospholipids 
present on the surface of cell membranes, and in doing so 
create a cascade of events that can lead to thrombosis, vas-
culopathy, inflammation, and a range pregnancy complica-
tions (Garcia and Erkan 2018). A recent systematic review 
aiming to examine all biomarkers of sPTB in human stud-
ies, from 1965 to 2008 (Menon et al. 2011), showed that 
55% of the biomarkers studied are involved with inflam-
mation and immune response, and that interleukin 6 (IL6), 
IL8 and corticotrophin-releasing hormone (CRH) were the 
most investigated biomarkers. The other biomarkers stud-
ied were involved in several other pathways, such as stress, 
hormonal metabolism, cellular metabolism, apoptosis, and 
placental dysfunction. In addition, proteins are the most 
studied type of biomarker in the articles included in this 
systematic review. The authors noted that none of these 
biomarkers showed the ability to predict sPTB accurately 
or help in better understanding the pathophysiology of this 
pregnancy adverse outcome. This shows how metabolomics 
based approaches could be better suited as biomarkers, since 
metabolites are a direct reflection of the cellular activity 
(Patti et al. 2012).
Our study has limitations, in particular the low number of 
sPTB samples with a delivery before 34 weeks of gestation, 
Fig. 3  Simplified overview of Glycerophospholipid and Sphingolipid metabolisms. PC phosphatidylcholine, PE phosphatidylethanolamine, PS 
phosphatidylserine, SM sphingomyelin, Palmitoyl-CoA palmitoyl coenzyme A
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which is attributed to the fact that the participants recruited 
for SCOPE were low-risk nulliparous women. Nevertheless, 
our study was well designed with a 1:2 case:control ratio, 
participants were carefully matched for BMI, age and ethnic-
ity, and we applied multiple testing to identify 27 significant 
features following multiple testing correction. Moreover, 
no additional findings were determined from the remaining 
metadata. Overall, our findings warrant replication in larger 
independent cohorts, using multi-omics measures to confirm 
dysregulation on a systems level, and explore whether the 
contribution of these 27 altered lipids is a cause or effect of 
preterm birth.
In conclusion, this study reports reduced glycerophospho-
lipids and sphingolipids at 20 weeks’ gestation, prior to the 
onset of sPTB in women in the Cork SCOPE study. Our find-
ings confirm and extend findings by Considine et al. (2019), 
suggesting convergent metabolomic and lipidomic pathways 
in the same cohort of women (Considine et al. 2019), which 
may serve as potential therapeutic targets or putative mark-
ers for the prediction of sPTB. Further research is needed to 
validate these findings in independent pregnancy cohorts.
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